SSA
EUCRU

Schonfeld Strategic Advisors’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Schonfeld Strategic Advisors’s Portfolio EUCRU Stock Details EUCRU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-300,000
Closed -$3.2M – 2222
2020
Q4 		$3.2M Buy
+300,000
New +$3.05M 0.04% 501

Other funds holding EUCRU

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Schonfeld Strategic Advisors's EUCRU Position: Q1 2021 in Review

Schonfeld Strategic Advisors sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q1 2021, closing a stake of 300,000 shares — an estimated $3.2M sold.

Schonfeld Strategic Advisors first reported a position in EUCRU in Q4 2020 and held it in 1 quarter. The position peaked at $3.2M in Q4 2020. 23 funds tracked by Wall St. Rank hold EUCRU as of Q1 2021.

  • Schonfeld Strategic Advisors reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q1 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 300,000 Eucrates Biomedical Acquisition Corp. Unit shares in Q1 2021, an estimated $3.2M.
  • Schonfeld Strategic Advisors first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Eucrates Biomedical Acquisition Corp. Unit position peaked at $3.2M in Q4 2020.
  • 23 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q1 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2021, filed 17 May 2021.